N-(3-甲氧基-4-硝基苯基)苯胺 | 723296-85-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(3-甲氧基-4-硝基苯基)苯胺
• 英文名称: 3-methoxy-4-nitro-N-phenylaniline
• 英文别名: (3-methoxy-4-nitro-phenyl)-phenyl-amine
• CAS: 723296-85-3
• 化学式: C₁₃H₁₂N₂O₃
• 分子量: 244.25
• InChiKey: HPORJFLJVQDEAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  67.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-甲氧基-4-硝基苯基)苯胺 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 24.0h， 以99%的产率得到4-氨基-3-甲氧基二苯胺
  参考文献：
  名称：

  신규 PPARδ 길항제 및 이를 포함하는 항암 효과 증진용 약학적 조성물

  摘要：

  This invention relates to a novel PPARδ antagonist compound, and its use for enhancing the resistance inhibition and anticancer effects of sorafenib in liver cancer. The compounds of the present invention can be advantageously used as pharmaceutical compositions for treating sorafenib-resistant progressive liver cancer.

  公开号：

  KR20210064526A
• 作为产物：
  描述：

  2-硝基-5-溴苯酚 在 palladium diacetate 、 potassium carbonate 、 caesium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 丙酮 、 甲苯 、 叔丁醇 为溶剂， 反应 21.0h， 生成 N-(3-甲氧基-4-硝基苯基)苯胺
  参考文献：
  名称：

  신규 PPARδ 길항제 및 이를 포함하는 항암 효과 증진용 약학적 조성물

  摘要：

  This invention relates to a novel PPARδ antagonist compound, and its use for enhancing the resistance inhibition and anticancer effects of sorafenib in liver cancer. The compounds of the present invention can be advantageously used as pharmaceutical compositions for treating sorafenib-resistant progressive liver cancer.

  公开号：

  KR20210064526A

文献信息

• Serebrjanyi, Ukrainskij Khimicheskij Zhurnal, 1955, vol. 21, p. 350,358
  作者：Serebrjanyi

  DOI：——

  日期：——
• 신규 PPARδ 길항제 및 이를 포함하는 항암 효과 증진용 약학적 조성물
  申请人：Kyungpook National University Industry-Academic Cooperation Foundation 경북대학교 산학협력단(220040016844) BRN ▼504-82-09678

  公开号：KR20210064526A

  公开（公告）日：2021-06-03

  본 발명은 신규한 PPARδ 길항제 화합물, 및 이의 소라페닙에 대한 간암의 내성 억제 및 항암 효과 증진 용도에 관한 것이다. 본 발명의 화합물은 소라페닙 내성 진행성 간암을 치료하기 위한 약학적 조성물로 유용하게 사용될 수 있다.

  This invention relates to a novel PPARδ antagonist compound, and its use for enhancing the resistance inhibition and anticancer effects of sorafenib in liver cancer. The compounds of the present invention can be advantageously used as pharmaceutical compositions for treating sorafenib-resistant progressive liver cancer.